Back to Cell Types

Panc 10.05Homo sapiens (Human)Cancer cell line

Also known as: PL-12, PL12, Pa16C, Panc1005, PANC1005, PANC 1005, PANC-10-05, Panc10.05, Panc-10.05

🤖 AI SummaryBased on 9 publications

Quick Overview

Human pancreatic cancer cell line with known genetic alterations

Detailed Summary

Panc 10.05 is a human pancreatic cancer cell line derived from a pancreatic tumor. It is characterized by specific genetic alterations, including gains and losses in chromosomal regions associated with pancreatic cancer progression. This cell line has been used in studies to investigate the molecular mechanisms underlying pancreatic cancer and to evaluate the efficacy of various chemotherapeutic agents. Research on Panc 10.05 has contributed to understanding the genetic complexity of pancreatic cancer and has been utilized in studies related to drug sensitivity and metabolic profiling.

Research Applications

Molecular cytogenetic analysisChemotherapy sensitivity testingMetabolic profilingGenetic subset identification

Key Characteristics

Chromosomal abnormalities associated with pancreatic cancerGenetic alterations in key cancer genesSensitivity to specific chemotherapeutic agentsMetabolic dependencies

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1639
Species	Homo sapiens (Human)
Tissue Source	Pancreas[UBERON:UBERON_0001264]

Donor Information

Age	81
Age Category	Adult
Sex	Male
Race	caucasian

Disease Information

Disease	Pancreatic ductal adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000060_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Ile255Asn (c.764T>A)	Homozygous	-	from autologous cell line Panc 10.05
MutationSimple	KRAS	p.Gly12Asp (c.35G>A)	Unspecified	-	PubMed=29786757

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

12

D12S391

17,20

D13S317

12

D16S539

9,12

D18S51

15

D19S433

13,14

D21S11

30

D2S1338

17,18

D3S1358

14

D5S818

13

D6S1043

17

D7S820

8,9

D8S1179

13,14

FGA

20

Penta D

12

Penta E

11,13

TH01

6,9.3

TPOX

11

vWA

16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.

Biankin A.V., Wu J.-M., Daly R.J.

Mol. Cell. Proteomics 15:2671-2685(2016).

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.

Iacobuzio-Donahue C.A., Eshleman J.R.

Clin. Cancer Res. 18:6519-6530(2012).

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations.

Ried T., Schrock E., Perlman E.J., Jaffee E.M.

Cytogenet. Genome Res. 118:148-156(2007).

Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.

Thomas M., Greten T.F., Hruban R.H., Yeo C.J., Griffin C.A.

Cancer J. Sci. Am. 4:194-203(1998).

Web Resources

dpsc.ccbr.utoronto.ca tcpaportal.org